Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Marcia Levenstein"'
Publikováno v:
Trials, Vol 22, Iss 1, Pp 1-5 (2021)
Abstract Background The sharing of individual participant-level data from COVID-19 trials would allow re-use and secondary analysis that can help accelerate the identification of effective treatments. The sharing of trial data is not the norm, but th
Externí odkaz:
https://doaj.org/article/19aae080d592480cbbb56851977ceb5d
Autor:
Amrutha Baskaran, Elizabeth Graham, Rebecca Li, Julie Wood, Stanley Neumann, Marcia Levenstein, Ida Sim
Publikováno v:
BMJ Open, Vol 10, Iss 10 (2020)
Objective Clinical trial data sharing has the potential to accelerate scientific progress, answer new lines of scientific inquiry, support reproducibility and prevent redundancy. Vivli, a non-profit organisation, operates a global platform for sharin
Externí odkaz:
https://doaj.org/article/e397bd77c5024bd8a8f6203a695aaf98
Publikováno v:
Perspectives in Clinical Research, Vol 4, Iss 4, Pp 221-226 (2013)
Aim: An effective clinical trial strategy to ensure patient safety as well as trial quality and efficiency involves an integrated approach, including prospective identification of risk factors, mitigation of the risks through proper study design and
Externí odkaz:
https://doaj.org/article/ba6cbde823b04a359bef4fe6683df17a
Autor:
Kristina Larson, Ida Sim, Megan von Isenburg, Marcia Levenstein, Frank Rockhold, Stan Neumann, Catherine D'Arcy, Elizabeth Graham, David Zuckerman, Rebecca Li
Publikováno v:
Contemporary Clinical Trials. 115:106709
This survey of COVID-19 interventional studies encompasses, and expands upon, a previous publication [1] examining individual participant level data (IPD) sharing intentions for COVID-related trials and publications prior to June 30, 2020.Replicating
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e97ffe54f8c1e525e7de719760dec87f
https://doi.org/10.1016/j.cct.2022.106709
https://doi.org/10.1016/j.cct.2022.106709
Autor:
Julie Wood, Ida Sim, Amrutha Baskaran, Elizabeth Graham, Stanley Neumann, Marcia Levenstein, Rebecca Li
Publikováno v:
BMJ Open, Vol 10, Iss 10 (2020)
BMJ Open
BMJ Open
ObjectiveClinical trial data sharing has the potential to accelerate scientific progress, answer new lines of scientific inquiry, support reproducibility and prevent redundancy. Vivli, a non-profit organisation, operates a global platform for sharing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f926dc1cb90d38ac6cfd563ce60582d6
https://bmjopen.bmj.com/content/10/10/e039326.full
https://bmjopen.bmj.com/content/10/10/e039326.full
Publikováno v:
Contemporary Clinical Trials. 39:28-33
The increased demand for transparency and disclosure of data from clinical trials sponsored by pharmaceutical companies poses considerable challenges and opportunities from a statistical perspective. A central issue is the need to protect patient pri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::156774d900a1b8c0312ef488bcb56167
https://doi.org/10.1016/j.cct.2014.07.002
https://doi.org/10.1016/j.cct.2014.07.002
Publikováno v:
American Heart Journal. 131:966-973
The Hypertension and Lipid Trial (HALT) was undertaken to assess the efficacy and safety of doxazosin, a selective alpha 1- adrenergic blocker, in patients with hypertension in a clinical practice setting. The effects of doxazosin on office blood pre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::203a3bd27f0e2c0dde47ee56ff79b3b8
https://doi.org/10.1016/s0002-8703(96)90181-7
https://doi.org/10.1016/s0002-8703(96)90181-7
Autor:
John E. Edwards, John H. Rex, Alan M. Sugar, C. Douglas Webb, W. Michael Scheld, Peter G. Pappas, Charles van der Horst, Adolf W. Karchmer, Marcia Levenstein, Ronald G. Washburn, Alan P. Dine, John E. Bennett
Publikováno v:
New England Journal of Medicine. 331:1325-1330
Background Amphotericin B has long been the standard treatment for candidemia, but its use is complicated by its toxicity. More recently, fluconazole, a water-soluble triazole with activity against candida species and little toxicity, has become avai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5284677fd157d2f5c25a8a41885cb31a
https://doi.org/10.1056/nejm199411173312001
https://doi.org/10.1056/nejm199411173312001
Publikováno v:
American Journal of Hypertension. 7:848-852
In this study the effects of a single daily dose of doxazosin (an alpha-adrenergic blocker) given at night were evaluated in 112 patients with mild hypertension. Patients were studied first on no medication, and a second time after being treated for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a16e8350e898b3ef6fa7d323291b8917
https://doi.org/10.1093/ajh/7.9.848
https://doi.org/10.1093/ajh/7.9.848
Publikováno v:
American Journal of Hypertension. 7:844-847
In this study the effects of a single daily dose (average 8.9 mg) of doxazosin (an alpha-adrenergic blocker) given at night were evaluated in 111 patients with mild hypertension. Patients were studied first on no medication, and a second time after b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2de667ce9a0ef2bcd48ab6233edc5d46
https://doi.org/10.1093/ajh/7.9.844
https://doi.org/10.1093/ajh/7.9.844